Concepedia

Relation of Improvement in Endothelium-Dependent Flow-Mediated Vasodilation After Rosiglitazone to Changes in Asymmetric Dimethylarginine, Endothelin-1, and C-Reactive Protein in Nondiabetic Patients With the Metabolic Syndrome

Tzung‐Dau Wang, Wen‐Jone Chen, Wern‐Cherng Cheng, Jong‐Wei Lin, Yuan‐Teh Lee

The American Journal of Cardiology · 2006 · 72 citations · 17 references

DOI

Concepts

References

17

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

, , +15

Plasma Adiponectin Levels and Risk of Myocardial Infarction in Men

Tobias Pischon · JAMA · 2004 · 1.8K citations · Full text

, , +9

Resistin Is an Inflammatory Marker of Atherosclerosis in Humans

Muredach P. Reilly, Michael Lehrke, Megan L. Wolfe et al. · Circulation · 2005 · 904 citations · Full text

, , +15

Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus

Steven M. Haffner, Andrew S. Greenberg, Wayde M. Weston et al. · Circulation · 2002 · 879 citations · Full text

, , +15

A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia

Ronald Goldberg, David M. Kendall, Mark A. Deeg et al. · Diabetes Care · 2005 · 795 citations · Full text

, , +14